PulseSight Therapeutics, PulseSight, PST-611, Geographic Atrophy, GA, Dry AMD, Age-Related Macular Degeneration, AMD, EURETINA 2026, Phase 1, Phase 2a

PARIS, France — October 7, 2026 PulseSight Therapeutics SAS presented new early clinical data from its PST-611 Phase 1...